Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 306 | 55 | 249 |
| Samples | 292 | 55 | 235 |
| Peptides | 168 | 33 | 148 |
Function
CXCR2 · C-X-C motif chemokine receptor 2
The protein encoded by this gene is a member of the G-protein-coupled receptor family. This protein is a receptor for interleukin 8 (IL8). It binds to IL8 with high affinity, and transduces the signal through a G-protein activated second messenger system. This receptor also binds to chemokine (C-X-C motif) ligand 1 (CXCL1/MGSA), a protein with melanoma growth stimulating activity, and has been shown to be a major component required for serum-dependent melanoma cell growth. This receptor mediates neutrophil migration to sites of inflammation. The angiogenic effects of IL8 in intestinal microvascular endothelial cells are found to be mediated by this receptor. Knockout studies in mice suggested that this receptor controls the positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. This gene, IL8RA, a gene encoding another high affinity IL8 receptor, as well as IL8RBP, a pseudogene of IL8RB, form a gene cluster in a region mapped to chromosome 2q33-q36. Alternatively spliced variants, encoding the same protein, have been identified. [provided by RefSeq, Nov 2009].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000318507 | P25025 | 306 | 168 |
Gene Properties
Recurrent Mutations
All 168 amino-acid changes on canonical ENST00000318507 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CXCR2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CXCR2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Melanoma | 6/210 3% | 59/1899 3% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Chondrosarcoma | 2/14 14% | 0/75 0% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Endometrial Carcinoma | 0/42 0% | 11/612 2% |
| Non-Small Cell Lung Carcinoma | 12/304 4% | 15/1390 1% |
| Osteosarcoma | 3/45 7% | 0/166 0% |
| Colorectal Carcinoma | 6/143 4% | 37/3239 1% |
| Gastric Carcinoma | 0/74 0% | 19/1809 1% |
| Ewings Sarcoma | 2/63 3% | 1/262 0% |
| Ovarian Carcinoma | 1/109 1% | 7/998 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 6/810 1% |
| Neuroendocrine Tumour | 2/154 1% | 3/577 1% |
| Other Solid Cancers | 0/94 0% | 10/1515 1% |
| Pancreatic Carcinoma | 3/89 3% | 7/1611 0% |
| Glioma | 2/52 4% | 9/2127 0% |
| Prostate Carcinoma | 1/13 8% | 9/2105 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Non-Cancerous | 1/104 1% | 3/830 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Hepatocellular Carcinoma | 0/46 0% | 8/2210 0% |
| B-Cell Non-Hodgkins Lymphoma | 7/88 8% | 1/2534 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 7/2550 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Head and Neck Carcinoma | 0/85 0% | 4/1574 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
Mutation Distribution
Where CXCR2 is mutated · all tissues, split by cell line vs tissue
How many mutations in CXCR2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 306 mutations in CXCR2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|